Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Get Rating) Director Niall O’donnell purchased 125,000 shares of the firm’s stock in a transaction that occurred on Monday, May 8th. The shares were bought at an average cost of $8.00 per share, for a total transaction of $1,000,000.00. Following the completion of the acquisition, the director now directly owns […]
Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif.,. | May 11, 2023
Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif., May
IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) Reneo Pharmaceuticals, Inc. (Reneo) (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies